• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在开伯尔-普赫图赫瓦省(KPK)的慢性 HCV 患者中,标准干扰素治疗的应答率。

Response rates of standard interferon therapy in chronic HCV patients of Khyber Pakhtunkhwa (KPK).

机构信息

Centre for Biotechnology and Microbiology, University of Peshawar, Peshawar, Khyber Pakhtunkhwa, Pakistan.

出版信息

Virol J. 2012 Jan 14;9:18. doi: 10.1186/1743-422X-9-18.

DOI:10.1186/1743-422X-9-18
PMID:22244529
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3284448/
Abstract

BACKGROUND

Interferon based therapy is used to eradicate the Hepatitis C Virus from the bodies of the infected individuals. HCV is highly prevalent in Khyber Pakhtunkhwa (KPK) that is why it is important to determine the response of standard interferon based therapy in Chronic HCV patients of the region.

STUDY DESIGN

A total of 174 patients were selected for interferon based therapy. The patients were selected from four different regions of KPK. After confirmation of active HCV infection by Real Time PCR, standard interferon with ribavirn was given to patients for 6 months. After completion of therapy, end of treatment virologic response (ETR) was calculated.

RESULTS

Out of total 174 patients, 130 (74.71%) showed ETR and 44 (25.28%) did not show ETR. In district Bunir, out of 52 patients, 36 (69.23%) showed ETR and 16 (30.79%) did not show ETR. In district Mardan, out of the total 74 patients, 66 (89.18%) were negative for HCV RNA and 8 (10.81%) were resistant to therapy. In Peshawar, out of 22, 16 (60%) were negative and 6 (40%) were positive for HCV RNA at the end of 6 months therapy. In the Federally Administered Tribal Area (FATA), out of 18 only 10 (55.5%) were negative and 8 (44.45%) were positive for active HCV infection.

CONCLUSION

It is concluded that the response of antiviral therapy against HCV infection in chronic HCV patients of KPK province is 74.71%. The high response rate may be due to the prevalence of IFN-responsive HCV genotypes (2 and 3) in KPK.

摘要

背景

基于干扰素的治疗用于清除感染个体体内的丙型肝炎病毒。在开伯尔-普赫图赫瓦省(开普省),丙型肝炎病毒的流行率很高,因此确定该地区慢性丙型肝炎患者对标准干扰素治疗的反应非常重要。

研究设计

共选择了 174 名患者接受基于干扰素的治疗。这些患者来自开普省的四个不同地区。在通过实时 PCR 确认丙型肝炎病毒的活性感染后,给予患者标准干扰素联合利巴韦林治疗 6 个月。完成治疗后,计算治疗结束时的病毒学应答(ETR)。

结果

在总共 174 名患者中,有 130 名(74.71%)显示 ETR,44 名(25.28%)未显示 ETR。在本尼尔区,52 名患者中,36 名(69.23%)显示 ETR,16 名(30.79%)未显示 ETR。在马尔丹区,74 名患者中,66 名(89.18%)对 HCV RNA 呈阴性,8 名(10.81%)对治疗耐药。在白沙瓦,22 名患者中有 16 名(60%)在 6 个月治疗结束时 HCV RNA 阴性,6 名(40%)阳性。在联邦直辖部落地区(FATA),只有 18 名患者中的 10 名(55.5%)对 HCV 感染呈阴性,8 名(44.45%)呈阳性。

结论

开普省慢性丙型肝炎患者抗病毒治疗对 HCV 感染的反应率为 74.71%。高反应率可能是由于开普省 IFN 反应性 HCV 基因型(2 和 3)的流行。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1610/3284448/51453222e2cc/1743-422X-9-18-1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1610/3284448/51453222e2cc/1743-422X-9-18-1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1610/3284448/51453222e2cc/1743-422X-9-18-1.jpg

相似文献

1
Response rates of standard interferon therapy in chronic HCV patients of Khyber Pakhtunkhwa (KPK).在开伯尔-普赫图赫瓦省(KPK)的慢性 HCV 患者中,标准干扰素治疗的应答率。
Virol J. 2012 Jan 14;9:18. doi: 10.1186/1743-422X-9-18.
2
Retreatment of hepatitis C patients with pegylated interferon combined with ribavirin in non-responders to interferon plus ribavirin. Is it different in real life?聚乙二醇干扰素联合利巴韦林治疗干扰素联合利巴韦林无应答的丙型肝炎患者。在现实生活中是否有所不同?
BMC Infect Dis. 2010 Jul 20;10:212. doi: 10.1186/1471-2334-10-212.
3
Effects of host and virus related factors on interferon-α+ribavirin and pegylated-interferon+ribavirin treatment outcomes in chronic Hepatitis C patients.宿主和病毒相关因素对慢性丙型肝炎患者干扰素-α+利巴韦林和聚乙二醇干扰素+利巴韦林治疗结局的影响。
Virol J. 2011 May 17;8:234. doi: 10.1186/1743-422X-8-234.
4
Frequency distribution of HCV genotypes among chronic hepatitis C patients of Khyber Pakhtunkhwa.在开伯尔-普赫图赫瓦省的慢性丙型肝炎患者中丙型肝炎基因型的频率分布。
Virol J. 2011 Apr 26;8:193. doi: 10.1186/1743-422X-8-193.
5
Hepatitis C Viral Kinetic Changes in a Retrospective Cohort Study of Chronic Hepatitis C Virus Egyptian Patients on Pegylated Interferon and Ribavirin Therapy.埃及慢性丙型肝炎病毒患者接受聚乙二醇干扰素和利巴韦林治疗的回顾性队列研究中丙型肝炎病毒动力学变化
J Interferon Cytokine Res. 2016 Mar;36(3):149-58. doi: 10.1089/jir.2015.0099.
6
Long-term follow-up of HIV-infected patients with chronic hepatitis C virus infection treated with interferon-based therapies.接受基于干扰素治疗的慢性丙型肝炎病毒感染的HIV感染患者的长期随访
Antivir Ther. 2004 Dec;9(6):987-92. doi: 10.1177/135965350400900616.
7
Long-term pegylated interferon monotherapy following 72 weeks of pegylated interferon and ribavirin in hepatitis C virus genotype-1-infected slow responders.在丙型肝炎病毒1型感染的慢反应者中,聚乙二醇化干扰素联合利巴韦林治疗72周后进行长期聚乙二醇化干扰素单药治疗。
Intern Med. 2015;54(3):273-9. doi: 10.2169/internalmedicine.54.2718.
8
Genotypes of hepatitis C virus in relapsed and non-respondent patients and their response to anti-viral therapy in district Mardan, Khyber Pakhtunkhawa, Pakistan.巴基斯坦开伯尔-普赫图赫瓦省马尔丹地区复发和无反应患者的丙型肝炎病毒基因型及其对抗病毒治疗的反应
Asian Pac J Cancer Prev. 2015;16(3):1037-40. doi: 10.7314/apjcp.2015.16.3.1037.
9
Therapeutic effectiveness of biosimilar standard interferon versus pegylated interferon for chronic hepatitis C genotypes 2 or 3.生物类似药标准干扰素与聚乙二醇干扰素治疗慢性丙型肝炎基因型 2 或 3 的疗效比较。
Braz J Infect Dis. 2012 May-Jun;16(3):232-6.
10
Predictive value of early viral dynamics during peginterferon and ribavirin combination therapy based on genetic polymorphisms near the IL28B gene in patients infected with HCV genotype 1b.基于 IL28B 基因附近遗传多态性的聚乙二醇干扰素和利巴韦林联合治疗方案对 1b 型 HCV 感染患者早期病毒动力学的预测价值。
J Med Virol. 2012 Jan;84(1):61-70. doi: 10.1002/jmv.22272.

引用本文的文献

1
Treatment of Hepatitis C Post-Liver Transplantation Could Mitigate Discard Rates of Hepatitis C-Positive Deceased Donor Livers and Expand the Donor Pool.肝移植后丙型肝炎的治疗可降低丙型肝炎阳性脑死亡供肝的废弃率并扩大供肝库。
J Transplant. 2021 Jan 25;2021:6612453. doi: 10.1155/2021/6612453. eCollection 2021.
2
Sero-Prevalence of Bloodborne Tumor Viruses (HCV, HBV, HTLV-I and KSHV Infections) and Related Risk Factors among Prisoners in Razavi Khorasan Province, Iran, in 2008.2008年伊朗拉扎维霍拉桑省囚犯中血源性肿瘤病毒(丙肝病毒、乙肝病毒、人类嗜T淋巴细胞病毒I型和卡波西肉瘤相关疱疹病毒感染)的血清流行率及相关危险因素
Hepat Mon. 2016 Dec 3;16(12):e31541. doi: 10.5812/hepatmon.31541. eCollection 2016 Dec.
3

本文引用的文献

1
Diagnosis, management, and treatment of hepatitis C: an update.丙型肝炎的诊断、管理与治疗:最新进展
Hepatology. 2009 Apr;49(4):1335-74. doi: 10.1002/hep.22759.
2
Peginterferon and ribavirin for chronic hepatitis C.聚乙二醇干扰素和利巴韦林治疗慢性丙型肝炎。
N Engl J Med. 2006 Dec 7;355(23):2444-51. doi: 10.1056/NEJMct061675.
3
Global challenges in liver disease.肝病领域的全球挑战。
Predictive potential of IL-28B genetic testing for interferon based hepatitis C virus therapy in Pakistan: Current scenario and future perspective.
IL-28B基因检测对巴基斯坦基于干扰素的丙型肝炎病毒治疗的预测潜力:现状与未来展望。
World J Hepatol. 2016 Sep 18;8(26):1116-8. doi: 10.4254/wjh.v8.i26.1116.
4
Oncogenic Virus Infections in the General Population and End-stage Renal Disease Patients With Special Emphasis on Kaposi's Sarcoma Associated Herpes Virus (KSHV) in Northeast of Iran.普通人群和终末期肾病患者中的致癌病毒感染,特别强调伊朗东北部的卡波西肉瘤相关疱疹病毒(KSHV)
Jundishapur J Microbiol. 2015 Mar 21;8(3):e14920. doi: 10.5812/jjm.14920. eCollection 2015 Mar.
5
Human T Lymphotropic Virus Type I (HTLV-I) Oncogenesis: Molecular Aspects of Virus and Host Interactions in Pathogenesis of Adult T cell Leukemia/Lymphoma (ATL).人类嗜T淋巴细胞病毒I型(HTLV-I)致癌作用:成人T细胞白血病/淋巴瘤(ATL)发病机制中病毒与宿主相互作用的分子层面
Iran J Basic Med Sci. 2013 Mar;16(3):179-95.
Hepatology. 2006 Sep;44(3):521-6. doi: 10.1002/hep.21347.
4
Treating viral hepatitis C: efficacy, side effects, and complications.治疗丙型病毒性肝炎:疗效、副作用及并发症
Gut. 2006 Sep;55(9):1350-9. doi: 10.1136/gut.2005.076646.
5
Management of patients with chronic hepatitis C infection.慢性丙型肝炎感染患者的管理。
Clin Exp Med. 2006 Mar;6(1):20-6. doi: 10.1007/s10238-006-0089-4.
6
Frequency of hepatitis "C" in Buner, NWFP.西北边境省布内尔地区丙型肝炎的发病率
J Coll Physicians Surg Pak. 2005 Jan;15(1):11-4.
7
PSG consensus statement on management of hepatitis C virus infection--2003.2003年丙型肝炎病毒感染管理的巴黎圣日耳曼共识声明
J Pak Med Assoc. 2004 Mar;54(3):146-50.
8
Diagnosis, management, and treatment of hepatitis C.丙型肝炎的诊断、管理与治疗。
Hepatology. 2004 Apr;39(4):1147-71. doi: 10.1002/hep.20119.
9
Global burden of disease (GBD) for hepatitis C.丙型肝炎的全球疾病负担(GBD)
J Clin Pharmacol. 2004 Jan;44(1):20-9. doi: 10.1177/0091270003258669.
10
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.聚乙二醇干扰素α-2a联合利巴韦林治疗慢性丙型肝炎病毒感染
N Engl J Med. 2002 Sep 26;347(13):975-82. doi: 10.1056/NEJMoa020047.